Only Eye Vitamin That Supports Two Health
Benefits in One, Clinically Proven AREDS 2 Formula for Eye Health
and 100 mg of CoQ10 Antioxidant for Heart Health*
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a
leading global eye health company dedicated to helping people see
better to live better, today announced the U.S. launch of
PreserVision® AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10).
Developed as a convenient two-in-one option, PreserVision AREDS 2
Formula eye vitamins plus CoQ10 is the only eye vitamin that
combines the exact nutrient formula recommended by the National Eye
Institute (NEI) to help reduce the risk of moderate to advanced
Age-related Macular Degeneration (AMD) progression in AMD patients
with CoQ10 to help support heart health.*1,2
AMD is a leading cause of vision loss in Americans who are 50
years of age or older3 and the leading cause of blindness for the
65+ population.4 People with AMD often have multiple conditions,
such as heart disease, which has similar risk factors to AMD.5 This
can lead to patients feeling overwhelmed as a result of the
numerous medications and supplements they may be required to
take.
“Heart disease is one of the top health concerns for AMD
patients, aside from doing all they can to help preserve their
sight,” said Rishi Singh, M.D., staff physician and president,
Cleveland Clinic Martin Hospitals, Stuart, Fla. “I encourage all my
AMD patients to maintain a healthy diet and make sure they are
exercising regularly, which are important actions they can take to
proactively support both conditions. AMD patients should also take
an eye vitamin with the proven nutrient formula such as
PreserVision® AREDS 2 vitamins to help reduce the risk of moderate
to advanced AMD progression. Now, with PreserVision AREDS 2 Formula
+ CoQ10, AMD patients have a convenient alternative that will help
ensure they receive their important nutrients for eye and heart
health every day.”*
CoQ10 is an antioxidant that the body produces naturally, which
helps support healthy cell function. Levels of CoQ10 in the body
decrease as people age, and they also tend to be lower in people
with certain conditions, such as heart disease, and in those who
take statins.6
“We are proud to offer eye care professionals and their patients
with this new option, which includes the same clinically proven
AREDS 2 formula eye vitamins plus CoQ10 to help support heart
health,”* said John Ferris, senior vice president, Consumer, Bausch
+ Lomb. “Americans over the age of 65 take more than five pills per
day on average, and as people age, their bodies naturally lose the
ability to keep up with their ongoing CoQ10 demand. In lieu of
taking extra supplements and to make it easier for people to stick
with their vitamin regimen, we developed this two-in-one formula to
help make it easier for them to support both their eye and heart
health.”
PreserVision® AREDS 2 Formula eye vitamins, including the new
PreserVision AREDS 2 formula with CoQ10, contain the exact nutrient
formula recommended by the NEI. This exact formula includes certain
amounts of lutein and zeaxanthin, which are two powerful
antioxidant carotenoids that have been clinically shown through
decades of research to help reduce the risk of progression in
people with moderate to advanced AMD. In 2022, the NEI’s AREDS2
10-Year Follow-on Study further confirmed the benefits of lutein
and zeaxanthin in the AREDS 2 formula.1
PreserVision AREDS 2 Formula soft gels with CoQ10 are now
available in the vitamin aisle or online at most major retailers
nationwide, including Walmart, Target and Amazon, and have a
manufacturer’s suggested retail price of $42.99. For more
information on PreserVision eye vitamins, visit
www.preservision.com.
*These statements have not been evaluated
by the Food and Drug Administration. This product is not intended
to diagnose, treat, cure or prevent any disease.
About AMD
AMD is a progressive eye condition that impacts central vision
and is a leading cause of blindness in adults 50 years of age and
older. Early-stage AMD often does not present any symptoms or
changes in vision, as symptoms usually appear gradually over time.
This progressive condition can impact one or both eyes, causing
people to have difficulty with daily activities like driving,
reading or recognizing the faces of loved ones.2
About PreserVision® AREDS 2 Formula Eye Vitamins
PreserVision® AREDS 2 formula eye vitamins, the most studied eye
vitamin brand, contain the exact NEI-recommended formula based on
the AREDS2 study. The daily dose (two capsules) of PreserVision®
AREDS 2 vitamins provides the exact same levels of all six
clinically proven nutrients as the NEI supported formula: vitamin C
(500mg), vitamin E (400 IU/180mg), lutein (10mg), zeaxanthin (2mg),
zinc (80mg zinc oxide), and copper (2mg cupric oxide). For more
information on PreserVision®, visit www.preservision.com.
About the AREDS, AREDS2 and 10-Year Follow-on AREDS2 Study
Results
The AREDS and AREDS2 studies are landmark clinical studies
conducted over 20 years by the NEI. The AREDS study in 2001
demonstrated that taking a specific combination of antioxidants and
zinc could help reduce the risk of progression of AMD in those with
moderate to advanced AMD. In 2012, the NEI completed the AREDS2
study, which tested several changes to the formulation, such as
adding omega-3 fatty acids, substituting lutein and zeaxanthin for
beta-carotene, and/or reducing zinc. The current AREDS2 nutrient
formula recommended by the NEI is the result of this study.
The NEI 10-Year Follow-on Study results evaluated the long-term
results of participants who were involved in the AREDS2 study.
Consisting of 3,883 people (6,351 study eyes) with moderate to
advanced AMD over a 10-year period, the follow-on study further
validates the original findings of the AREDS2 formulation with
lutein and zeaxanthin, demonstrating an incremental reduction in
risk of the progression to late-stage AMD.1
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift
of sight for millions of people around the world – from the moment
of birth through every phase of life. Its comprehensive portfolio
of more than 400 products includes contact lenses, lens care
products, eye care products, ophthalmic pharmaceuticals,
over-the-counter products and ophthalmic surgical devices and
instruments. Founded in 1853, Bausch + Lomb has a significant
global research and development, manufacturing and commercial
footprint with approximately 13,000 employees and a presence in
nearly 100 countries. Bausch + Lomb is headquartered in Vaughan,
Ontario with corporate offices in Bridgewater, New Jersey. For more
information, visit www.bausch.com and connect with us on Twitter,
LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words “anticipates,”
“hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,”
“may,” “believes,” “estimates,” “potential,” “target,” or
“continue” and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb’s filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties caused by or
relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on Bausch +
Lomb, including but not limited to its project development
timelines, launches and costs (which may increase). Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Bausch + Lomb undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
References
1. Chew EY, Clemons TE, Agrón E, et al.
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids
to the AREDS Supplements on Age-Related Macular Degeneration
Progression: AREDS2 Report 28. JAMA Ophthalmology.
2022;140(7):692–698. doi:10.1001/jamaophthalmol.2022.1640.
2. National Eye Institute Website.
Retrieved from
https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration.
Accessed May 25, 2023.
3. Prevent Blindness: Age-Related Macular
Degeneration Fact Sheet:
https://preventblindness.org/wp-content/uploads/2021/01/PBAMD_Fact-Sheet21.pdf.
4. Centers For Disease Control and
Prevention Website. Retrieved from
https://www.cdc.gov/visionhealth/resources/features/macular-degeneration.html#:~:text=AMD%20is%20a%20major%20cause,vision%20needed%20to%20see%20clearly.
Accessed May 25, 2023.
5. Mauschitz, Matthias M. MD, PhD; Finger,
Robert P. MD, PhD. Age-Related Macular Degeneration and
Cardiovascular Diseases: Revisiting the Common Soil Theory.
Asia-Pacific Journal of Ophthalmology 11(2):p 94-99, March-April
2022.
6. Aaseth J, Alexander J, Alehagen U.
Coenzyme Q10 supplementation - In ageing and disease. Mech Ageing
Dev. 2021 Jul;197:1-7.
AREDS and AREDS2 are registered trademarks of the United States
Department of Health and Human Services (HHS).
© 2023 Bausch + Lomb. PV2.0058.USA.23
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230612936776/en/
Investor Contact: Allison Ryan allison.ryan@bausch.com
(877) 354-3705 (toll free) (908) 927-0735
Media Contacts: Lainie Keller lainie.keller@bausch.com
(908) 927-1198
Kristy Marks kristy.marks@bausch.com (908) 927-0683
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024